Ansornitinib

• CAT Number: I043421
• CAS Number: 1448874-96-1
• Molecular Formula: C30H32N6O4
• Molecular Weight: 540.61
• Purity: ≥95%
• Synonyms: methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-pyrrolo[2,3-b]pyridine-6-carboxylate
• InChI: InChI=1S/C30H32N6O4/c1-34-15-17-36(18-16-34)19-25(37)35(2)22-11-9-21(10-12-22)31-27(20-7-5-4-6-8-20)26-23-13-14-24(30(39)40-3)32-28(23)33-29(26)38/h4-14,38H,15-19H2,1-3H3,(H,32,33)
• InChIKey: CIBINADBMIHXHZ-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=N5)C(=O)OC)O

Ansornitinib（Cat No.:I043421）is an investigational small molecule kinase inhibitor being studied for its potential in cancer therapy. It targets specific receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis, and metastasis, such as VEGFR and PDGFR. By inhibiting these pathways, Ansornitinib may help block the blood supply to tumors, slow cancer cell proliferation, and reduce tumor spread. Research is ongoing to assess its efficacy and safety across various cancer types, including solid tumors. Ansornitinib has the potential to offer a new therapeutic approach for patients with cancers resistant to existing treatments.